Zineb Belcaid Selected Research

Therapeutics

11/2020	Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.
1/2020	Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy.
6/2019	Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
1/2018	Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system.
1/2018	TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.
1/2016	Ganetespib radiosensitization for liver cancer therapy.
1/2014	Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zineb Belcaid Research Topics

Disease

17	Neoplasms (Cancer) 02/2022 - 01/2011
8	Glioblastoma (Glioblastoma Multiforme) 02/2022 - 01/2011
7	Glioma (Gliomas) 02/2022 - 06/2013
2	Melanoma (Melanoma, Malignant) 02/2022 - 11/2020
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2020
2	Brain Neoplasms (Brain Tumor) 12/2019 - 06/2013
1	Malignant Mesothelioma 11/2021
1	Mesothelioma 11/2021
1	Human Influenza (Influenza) 01/2021
1	Liver Neoplasms (Liver Cancer) 01/2016
1	Experimental Melanoma 01/2014

Drug/Important Bio-Agent (IBA)

7	Immune Checkpoint InhibitorsIBA 02/2022 - 01/2018
2	Programmed Cell Death 1 ReceptorIBA 02/2022 - 01/2018
2	LuciferasesIBA 02/2022 - 06/2013
2	B7-H1 AntigenIBA 01/2022 - 12/2019
2	LigandsIBA 01/2018 - 06/2013
1	Glutamic Acid (Glutamate)FDA Link 02/2022
1	PlatinumIBA 11/2021
1	durvalumabIBA 11/2021
1	Pemetrexed (MTA)FDA Link 11/2021
1	Interleukin-7 (Interleukin 7)IBA 01/2021
1	AntibodiesIBA 01/2020
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020
1	3-chloro-2,5,6-trimethylbenzoateIBA 01/2020
1	Immunoglobulins (Immunoglobulin)IBA 12/2019
1	MucinsIBA 12/2019
1	Monoclonal AntibodiesIBA 12/2018
1	Poly I-CIBA 04/2018
1	Therapeutic UsesIBA 01/2018
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018
1	Temozolomide (Temodar)FDA LinkGeneric 06/2017
1	Proteins (Proteins, Gene)FDA Link 01/2016
1	STA 9090IBA 01/2016
1	Molecular Chaperones (Chaperone, Molecular)IBA 01/2016
1	geldanamycinIBA 01/2016
1	Blocking AntibodiesIBA 01/2014
1	CTLA-4 AntigenIBA 01/2014
1	AntigensIBA 01/2014
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2013
1	InterferonsIBA 06/2013
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 12/2012
1	Small Interfering RNA (siRNA)IBA 12/2012

Therapy/Procedure

10	Immunotherapy 02/2022 - 01/2011
7	Therapeutics 11/2020 - 01/2014
4	Radiotherapy 01/2020 - 06/2013
2	Drug Therapy (Chemotherapy) 11/2021 - 06/2017
1	Injections 08/2014